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tions, reﬂecting differences in early time points and in illness
severity levels. For schizophrenia patients with at least moderate
symptom severity, the lack of at least 14–23% improvement on
the PANSS total score at two weeks is an optimal predictor of
subsequent non-response following eight weeks of treatment.
This early response threshold appears to be an important clinical
marker of subsequent non-response to antipsychotic therapy.
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OBJECTIVE: To evaluate the 12-month clinical and functional
outcomes in patients with schizophrenia who received RLAI
treatment and were enrolled in the electronic-Schizophrenia
Treatment Adherence Registry (e-STAR) in Australia and
Belgium, and the Schizophrenia Outcomes Utilization, Relapse,
and Clinical Evaluation (SOURCE) in the United States.
METHODS: e-Star and SOURCE are long-term, prospective,
observational studies of patients with schizophrenia who com-
mence RLAI treatment. Data are collected both retrospectively
and prospectively and clinical effectiveness was measured by the
Clinical Global Impression Severity (CGI-S) scale and patient
functioning was measured by the Global Assessment of Function-
ing (GAF) scale. RESULTS: Seven hundred sixty-nine patients
(Australia = 493, Belgium = 163, USA = 113) with 12-months
of follow-up data were included. Australia had signiﬁcantly
younger patients than Belgium and the United States (mean ages:
Australia = 38.6, Belgium = 41.6, USA = 43.5; p = 0.0003). Time
since diagnosis (in years) was signiﬁcantly higher in the United
States than Australia and Belgium (USA = 17.6, Australia = 11.6,
Belgium = 9.8; p < 0.0001). United Stats patients had signiﬁ-
cantly higher baseline GAF scores than the Australian and
Belgian patients (USA = 50.9, Australia = 42.7, Belgium = 43.1;
p < 0.0001). Despite baseline differences, GAF and CGI-S scores
at 12-months for patients treated with RLAI signiﬁcantly
improved from baseline in all three countries. CGI-S scores sig-
niﬁcantly decreased by 0.8 (p < 0.001), 1.08 (p < 0.001) and
0.83 (p < 0.001) points and GAF scores signiﬁcantly increased by
12.7 (p < 0.001), 14.8 (p < 0.001), and 11.1 (p < 0.001) points in
Australia, Belgium, and the United States respectively. CON-
CLUSION: This interim analysis from the two observational
studies shows that despite differences in patient characteristics
among countries, treatment with RLAI resulted in signiﬁcant
improvements in disease severity and patient functioning in
patients with schizophrenia from all three countries.
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OBJECTIVE: To assess differences in treatment duration and
resource utilization following initiation on atypical antipsychot-
ics among schizophrenia patients with versus without metabolic
syndrome who were treated at the Veteran Health Administra-
tion. METHODS: We used electronic medical records data for
October 2002-August 2005 from a large Veterans Integrated
Service Network (VISN16) to identify schizophrenia patients
who were initiated on an atypical antipsychotic and have under-
gone metabolic monitoring in the 180 days prior to medication
initiation. Those found to have a metabolic syndrome (MetSyn+)
were compared to those without (MetSyn-) on patient charac-
teristics, treatment duration, medication adherence per medica-
tion possession ratio (MPR), and resource utilization in the
1-year post medication initiation. Kaplan-Meyer (K-M) estima-
tion compared the difference in treatment duration. A Cox pro-
portional hazard regression was used to compare all-cause
medication discontinuation, controlling for group differences at
baseline. RESULTS: A minority of schizophrenia patients who
have undergone metabolic monitoring was found to have a meta-
bolic syndrome (83 of 593, or 14.0%). The MetSyn+ and
MetSyn- groups did not signiﬁcantly differ on baseline charac-
teristics except that the MetSyn+ group had a higher rate of
non-VA insurance. Adherence (MPR) during the year following
medication initiation was higher for the MetSyn+ group (81% vs.
68%; p = 0.031). K-M estimators (log-rank test p = 0.471; Wil-
coxon test p = 0.512) and a Cox model (p = 0.671) indicated
lack of statistically signiﬁcant group difference in all-cause medi-
cation discontinuation. CONCLUSION: Among schizophrenia
patients who have undergone metabolic monitoring, those with a
metabolic syndrome and those without do not appear to differ on
treatment duration and resource utilization following initiation
on an atypical antipsychotic medication in the Veterans Health
Administration.
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OBJECTIVE: Continuous treatment is an important goal in the
management of schizophrenia. Retention rate is a well-recognized
global measure of effectiveness that integrates patients’ and clini-
cians’ judgment of efﬁcacy, safety and tolerability. Furthermore,
all-cause discontinuation was used as a primary outcomemeasure
in a large effectiveness study (Clinical Antipsychotic trial of Inter-
vention Effectiveness or CATIE). The current study utilized lon-
gitudinal claims data fromOntario Drug Beneﬁt (ODB) recipients
in Ontario, Canada to compare retention rates for typical and
atypical antipsychotic medications with different formulations.
METHODS: Longitudinal data were obtained for ODB recipients
that were initiated on antipsychotic therapy in July 2006. ODB
recipients were followed from their ﬁrst claim for the speciﬁc
target drug to their last claim in a 12-month period. Rates of
retention were determined throughout and up until 12 months.
Descriptive analyses were performed. Retention rates were
reported for depot (long-acting injectable) risperidone; oral atypi-
cal antipsychotics including olanzapine, risperidone, and quetiap-
ine; orally disintegrating tablet formulations of risperidone and
olanzapine; oral typical antipsychotics (pooled); and depot typical
antipsychotics (pooled). RESULTS: From July 2006–June 2007,
12-month retention rates were lowest with oral typical (29% of
recipients), depot typical antipsychotics (30%), and risperidone
orally disintegrating formulations (30%). Retention rates for oral
atypical antipsychotics were 41% for olanzapine, 46% for risperi-
done and 50% for quetiapine. Retention on risperidone long-
acting injectable were the highest with 73% of recipients retained
over 12-months. CONCLUSION: Retention rates were lowest
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with typical antipsychotics and risperidone orally disintegrating
tablets and highest with depot risperidone formulation. This
ﬁnding is consistent with the results reported in the CATIE study
where only 25–45% of patients continued on oral treatment after
one year. Retention on medication is an important aspect of
patient outcomes in schizophrenia; these data suggest that reten-
tion on depot risperidone may be improved compared to other
treatments.
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OBJECTIVE: To identify treatment patterns and illness charac-
teristics preceding the initiation of depot typical antipsychotics in
the treatment of schizophrenia patients who are non-adherent
with oral antipsychotic regimens. METHODS: Data were drawn
from a large, multi-site, 3-year prospective non-interventional
observational study of schizophrenia patients in the U.S, con-
ducted between July 1997 and September 2003. The analytical
sample included patients who—in the six months prior to
enrollment—were non-adherent with oral antipsychotics and
were not treated with depot antipsychotics (N = 314). Non-
adherent patients who were subsequently initiated on typical
depots during the 3-year follow-up were compared with patients
continuing therapy with only oral agents. Comparisons were
made on clinical, functional, and treatment variables assessed at
predetermined intervals with standard psychiatric measures, a
patient self-report questionnaire, and medical record informa-
tion. RESULTS: A small proportion of patients (12.4%) previ-
ously non-adherent with oral antipsychotics were subsequently
initiated on a depot therapy during the 3-year study. Compared
to patients treated with only oral antipsychotics, those subse-
quently initiated on a depot were signiﬁcantly more likely to be
hospitalized at depot initiation or during the previous six
months, were more likely to have recent legal involvement, illicit
drug use, and treatment with more antipsychotics during the 3
months prior to initiation. CONCLUSION: Despite prior non-
adherence with antipsychotic medication, only a small propor-
tion of non-adherent schizophrenia patients were initiated on
depot antipsychotics in this 3-year prospective study. Patients
who were subsequently initiated on depot had a distinct treat-
ment pattern and illness proﬁle preceding initiation of the depot
medication.
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OBJECTIVES: To assess the reporting and scientiﬁc quality of
meta-analyses (MAs) of randomized controlled trials (RCTs) as
treatments for anxiety disorders. METHODS: We searched
EMBASE, EBM Reviews, MEDLINE, Healthstar and IPA from
inception to August 2007. Search terms included: MA, RCTs,
anxiety, anxiolytic, anti-depressant/antidepressant and cognitive
therapy with no language restrictions. Titles and abstracts were
assessed by two reviewers independently. Criteria for full-text
retrieval included: MA, statistical pooling, anxiety disorder,
RCT, pharmacotherapy, cognitive therapy. RCTs examining
anxiety symptoms were excluded. A manual search of refer-
ences was performed. Quality was assessed independently by
two raters, using the Quality of Reporting of Meta-analyses
checklist (QUOROM) and the Overview Quality Assessment
Questionnaire (OQAQ). Kendall’s tau measured inter-rater reli-
ability with statistical signiﬁcance at P  0.05. Means and stan-
dard deviations described the overall quality. A time series
analysis was performed. RESULTS: In total, 136 titles and
abstracts were reviewed; 48 were retrieved, including six from
the manual search. Twelve were excluded (not pooled analyses,
inappropriate condition or treatment or were duplicates),
leaving 36 studies. Publication dates ranged from 1990–2007.
Agreement was high; tau = 0.856 (P < 0.05) for QUOROM and
0.865 (P < 0.05) for OQAQ. The mean overall QUOROM
score was 65% (SD = 18%). The ‘results’ category yielded the
lowest quality scores while the introductions and discussions
yielded the highest. The mean overall OQAQ score was 59%
(SD = 25%). Flaws in scientiﬁc quality were observed regard-
ing ‘avoidance of bias’ and ‘validity’ while most studies linked
the results to the primary objective appropriately. There was
a small, non-signiﬁcant increase in quality of MAs over the
years observed. CONCLUSIONS: Reporting and scientiﬁc
quality of MAs in anxiety were only fair. They were, however,
higher than those previously reported for depression and criti-
cal care.
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OBJECTIVE: To evaluate clinical and functioning outcomes of
risperidone long-acting injection (RLAI) treatment in patients
with schizophrenia enrolled in the electronic-Schizophrenia
Treatment Adherence Registry (e-STAR) from Czech Republic
and Slovakia. METHODS: e-STAR is an international, long-
term, prospective, observational study of patients with schizo-
phrenia who commence RLAI treatment. Data are collected
retrospectively for one year and prospectively every three months
for two years. Clinical outcomes were measured by Clinical
Global Impression-Severity (CGI-S) scale and patient functioning
was assessed using Global Assessment of Functioning (GAF)
scale. This interim report is based on data from patients who
have completed their 18-month follow-up visit. RESULTS: To
date, a total of 1324 patients have been enrolled in e-STAR from
the Czech Republic and Slovakia; 296 patients with at least
18-months of data available (97.3% still on RLAI) were included
in this analysis. Of the 296 patients, 53.7% were male with a
mean age of 37.6  12.0 years and a mean time since diagnosis
of 9.6  9.0 years. Mean CGI-S score signiﬁcantly decreased
from 4.6 plusmn; 1.1 at baseline to 2.9  1.0 at 18 months
(p < 0.001). Proportion of patients with not ill/very mild/mild
illness increased from 13.5% to 75.6% and that of patients with
marked/severe/extremely severe decreased from 48.8% to
6.3% (p < 0.001) compared to baseline. Meanwhile, patient
global functioning has signiﬁcantly improved as the mean GAF
score increased signiﬁcantly from 49.9  15.2 at baseline to
73.8  14.5 at 18 months (p < 0.001). CONCLUSION: Signiﬁ-
cant improvements in disease severity and functioning from base-
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